Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
St. Luke's Hospital Cancer Center
mi
from
Bethlehem, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
St. Luke's Hospital Cancer Center
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Geisinger Medical Center
mi
from
Danville, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Mercy Fitzgerald Hospital
mi
from
Darby, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Mercy Fitzgerald Hospital
mi
from
Darby, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Delaware County Memorial Hospital
mi
from
Drexel Hill, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Delaware County Memorial Hospital
mi
from
Drexel Hill, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Pocono Cancer Center
mi
from
East Stroudsburg, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Pocono Cancer Center
mi
from
East Stroudsburg, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Abramson Cancer Center of the University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Abramson Cancer Center of the University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Veterans Affairs Medical Center - Philadelphia
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Veterans Affairs Medical Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Allegheny General Hospital
mi
from
Pittsburgh, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Mercy Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Mercy Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Hillman Cancer Center at University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Reading Hospital and Medical Center
mi
from
Reading, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Reading Hospital and Medical Center
mi
from
Reading, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Mercy Hospital Cancer Center - Scranton
mi
from
Scranton, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Mercy Hospital Cancer Center - Scranton
mi
from
Scranton, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Wilkes Barre General Hospital
mi
from
Wilkes-Barre, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Wilkes Barre General Hospital
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - MainLine Health
mi
from
Wynnewood, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - MainLine Health
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Wellspan Health - York Cancer Center
mi
from
York, PA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Wellspan Health - York Cancer Center
mi
from
York, PA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Roger Williams Medical Center
mi
from
Providence, RI
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Greenville
mi
from
Greenville, SC
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
CCOP - Upstate Carolina
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
West Tennessee Cancer Center at Jackson-Madison County General Hospital
mi
from
Jackson, TN
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
West Tennessee Cancer Center at Jackson-Madison County General Hospital
mi
from
Jackson, TN
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
mi
from
Nashville, TN
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Harrington Cancer Center
mi
from
Amarillo, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Harrington Cancer Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Arlington Cancer Center
mi
from
Arlington, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Arlington Cancer Center
mi
from
Arlington, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Wilford Hall Medical Center
mi
from
Lackland Air Force Base, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Wilford Hall Medical Center
mi
from
Lackland Air Force Base, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Bayshore Medical Center
mi
from
Pasadena, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Bayshore Medical Center
mi
from
Pasadena, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Utah Valley Regional Medical Center - Provo
mi
from
Provo, UT
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Utah Valley Regional Medical Center - Provo
mi
from
Provo, UT
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Dixie Regional Medical Center
mi
from
Saint George, UT
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Dixie Regional Medical Center
mi
from
Saint George, UT
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
LDS Hospital
mi
from
Salt Lake City, UT
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Green Mountain Oncology Group
mi
from
Bennington, VT
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Green Mountain Oncology Group
mi
from
Bennington, VT
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Vermont Cancer Center at University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Cancer Center at the University of Virginia
mi
from
Charlottesville, VA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Cancer Center at the University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
RMH Regional Cancer Center
mi
from
Harrisonburg, VA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
RMH Regional Cancer Center
mi
from
Harrisonburg, VA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Naval Medical Center - Portsmouth
mi
from
Portsmouth, VA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Naval Medical Center - Portsmouth
mi
from
Portsmouth, VA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Bon Secours St. Mary's Hospital
mi
from
Richmond, VA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Bon Secours St. Mary's Hospital
mi
from
Richmond, VA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Massey Cancer Center, Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Cancer Institute at Virginia Mason Medical Center
mi
from
Seattle, WA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Cancer Institute at Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
University Cancer Center at University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Deaconess Medical Center
mi
from
Spokane, WA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Deaconess Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Yakima Valley Memorial Hospital
mi
from
Yakima, WA
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Yakima Valley Memorial Hospital
mi
from
Yakima, WA
Click here to add this to my saved trials
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated:  10/2/2017
Schiffler Cancer Center
mi
from
Wheeling, WV
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Status: Enrolling
Updated: 10/2/2017
Schiffler Cancer Center
mi
from
Wheeling, WV
Click here to add this to my saved trials